FI963475L - Fibroblastin kasvutekijä 10 - Google Patents

Fibroblastin kasvutekijä 10 Download PDF

Info

Publication number
FI963475L
FI963475L FI963475A FI963475A FI963475L FI 963475 L FI963475 L FI 963475L FI 963475 A FI963475 A FI 963475A FI 963475 A FI963475 A FI 963475A FI 963475 L FI963475 L FI 963475L
Authority
FI
Finland
Prior art keywords
growth factor
fibroblast growth
fibroblast
factor
growth
Prior art date
Application number
FI963475A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963475A7 (fi
FI963475A0 (fi
Inventor
Jing-Shan Hu
Jeannine D Gocayne
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of FI963475A0 publication Critical patent/FI963475A0/fi
Publication of FI963475A7 publication Critical patent/FI963475A7/fi
Publication of FI963475L publication Critical patent/FI963475L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI963475A 1994-03-08 1995-03-08 Fibroblastin kasvutekijä 10 FI963475L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/207,412 US5817485A (en) 1994-03-08 1994-03-08 Nucleic acids and cells for recombinant production of fibroblast growth factor-10
PCT/US1995/002950 WO1995024414A1 (en) 1994-03-08 1995-03-08 Fibroblast growth factor-10

Publications (3)

Publication Number Publication Date
FI963475A0 FI963475A0 (fi) 1996-09-05
FI963475A7 FI963475A7 (fi) 1996-11-05
FI963475L true FI963475L (fi) 1996-11-05

Family

ID=22770445

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963475A FI963475L (fi) 1994-03-08 1995-03-08 Fibroblastin kasvutekijä 10

Country Status (21)

Country Link
US (2) US5817485A (cs)
EP (2) EP1380594A1 (cs)
JP (2) JPH09510103A (cs)
CN (1) CN1150804A (cs)
AT (1) ATE251637T1 (cs)
AU (1) AU1986195A (cs)
CA (1) CA2183961A1 (cs)
CZ (1) CZ260696A3 (cs)
DE (1) DE69531892T2 (cs)
DK (1) DK0750628T3 (cs)
ES (1) ES2208676T3 (cs)
FI (1) FI963475L (cs)
HU (1) HUT77578A (cs)
IL (1) IL112878A0 (cs)
MX (1) MX9603897A (cs)
NO (1) NO963728L (cs)
PL (1) PL316202A1 (cs)
PT (1) PT750628E (cs)
SK (1) SK112996A3 (cs)
WO (1) WO1995024414A1 (cs)
ZA (1) ZA951886B (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
EP0751992B1 (en) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
KR19990008319A (ko) * 1995-06-05 1999-01-25 벤슨로버트에이치 섬유아세포 성장 인자 15
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6020189A (en) * 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
JPH10279501A (ja) * 1997-02-10 1998-10-20 Rohto Pharmaceut Co Ltd 育毛剤
US6335317B1 (en) * 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
JP2004505619A (ja) 2000-08-04 2004-02-26 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
KR101187871B1 (ko) 2009-09-23 2012-10-05 (주)케어젠 Ｆｇｆ１０－유래 펩타이드 및 그의 용도
JP2013544361A (ja) * 2010-11-23 2013-12-12 ケーシーアイ ライセンシング インク バイオマーカーを用いた創傷の診断及び治療用の装置及び方法
CN103169658A (zh) * 2012-10-26 2013-06-26 温州医学院 成纤维细胞生长因子-10脂质体制备及在毛发再生中的应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells

Also Published As

Publication number Publication date
JPH09510103A (ja) 1997-10-14
HU9602434D0 (en) 1996-11-28
FI963475A7 (fi) 1996-11-05
CZ260696A3 (en) 1997-05-14
DE69531892T2 (de) 2004-07-22
CA2183961A1 (en) 1995-09-14
AU1986195A (en) 1995-09-25
DE69531892D1 (de) 2003-11-13
EP0750628A4 (en) 1997-06-11
CN1150804A (zh) 1997-05-28
WO1995024414A1 (en) 1995-09-14
IL112878A0 (en) 1995-06-29
DK0750628T3 (da) 2004-02-02
PT750628E (pt) 2004-03-31
NO963728D0 (no) 1996-09-06
ZA951886B (en) 1996-09-09
JP2002335982A (ja) 2002-11-26
PL316202A1 (en) 1996-12-23
EP0750628B1 (en) 2003-10-08
FI963475A0 (fi) 1996-09-05
MX9603897A (es) 1997-07-31
SK112996A3 (en) 1997-01-08
NO963728L (no) 1996-11-07
ES2208676T3 (es) 2004-06-16
EP0750628A1 (en) 1997-01-02
EP1380594A1 (en) 2004-01-14
HUT77578A (hu) 1998-06-29
US5817485A (en) 1998-10-06
US20020034787A1 (en) 2002-03-21
ATE251637T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
FI963475A7 (fi) Fibroblastin kasvutekijä 10
DE59605821D1 (de) l/4-SCALLABSORBER
EP0751770A4 (en) 8-SUBSTITUTED TETRAHYDRO BETA CARBOLINE
NO930926D0 (no) 2-oksokinolinderivater
NO992059D0 (no) 2-metoksyfenylpiperazinderivater
FI954252A7 (fi) Luukasvutekijä
DE69503614D1 (de) Supraleitender übergang
FR2727855B1 (fr) Implants d'extension caverneuse
EP0833904A4 (en) FIBROBLAST GROWTH FACTOR-14
EP0832215A4 (en) FIBROBLAST GROWTH FACTOR 11
FI953784A7 (fi) 3'-atsiridinoantrasykliinijohdannaiset
DE69534958D1 (de) Modifiziertes Epimorphin
EP0832216A4 (en) FIBROBLASTER GROWTH FACTOR
BR9709521A (pt) "3-Cianoaril-pirazóis"
DE69636232D1 (de) Wachstumsfaktor htter36
ITCT920024A0 (it) Denti-salva 1
FI933290A0 (fi) 21-klorpregnanderivat
ITTO940810A0 (it) "sedia"
ITCB940003U3 (it) Lamaspirale 1
ITFE940002A0 (it) Walk-system 1
ATE328892T1 (de) Wachstumsfaktor htter36
BR7401400U (pt) "Cool-fast
UA680S (uk) Судно-службово-роз'їздне
UA27881C2 (uk) Мийно-дезінфекційний засіб "збруч-2"
ITCT940031A0 (it) "sbufi"

Legal Events

Date Code Title Description
FD Application lapsed